Biotech’s pro-cyclical talent contract is an innovation tax

Key Points

• Pro-cyclical talent contracts may hinder innovation within the biotech industry, affecting overall productivity.
• Key evidence shows that during economic booms, talent contracts become more stringent, potentially stifling creativity.
• Analysis of labor market dynamics across various biotech firms highlights the adverse effects of rigid talent agreements.
• This situation underscores the challenges of balancing talent acquisition with innovation potential in a volatile market.